HUP0301690A3 - Synergistic methods and compositions for treating cancer - Google Patents

Synergistic methods and compositions for treating cancer

Info

Publication number
HUP0301690A3
HUP0301690A3 HU0301690A HUP0301690A HUP0301690A3 HU P0301690 A3 HUP0301690 A3 HU P0301690A3 HU 0301690 A HU0301690 A HU 0301690A HU P0301690 A HUP0301690 A HU P0301690A HU P0301690 A3 HUP0301690 A3 HU P0301690A3
Authority
HU
Hungary
Prior art keywords
compositions
treating cancer
synergistic methods
synergistic
methods
Prior art date
Application number
HU0301690A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of HUP0301690A2 publication Critical patent/HUP0301690A2/hu
Publication of HUP0301690A3 publication Critical patent/HUP0301690A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HU0301690A 2000-03-27 2001-03-22 Synergistic methods and compositions for treating cancer HUP0301690A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19227800P 2000-03-27 2000-03-27
PCT/US2001/009193 WO2001072721A2 (en) 2000-03-27 2001-03-22 Synergistic methods and compositions for treating cancer

Publications (2)

Publication Number Publication Date
HUP0301690A2 HUP0301690A2 (hu) 2003-08-28
HUP0301690A3 true HUP0301690A3 (en) 2005-05-30

Family

ID=22709017

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301690A HUP0301690A3 (en) 2000-03-27 2001-03-22 Synergistic methods and compositions for treating cancer

Country Status (24)

Country Link
US (1) US6537988B2 (enExample)
EP (1) EP1272193B1 (enExample)
JP (1) JP5110756B2 (enExample)
KR (1) KR20020084254A (enExample)
CN (1) CN100384424C (enExample)
AR (1) AR028296A1 (enExample)
AT (1) ATE430570T1 (enExample)
AU (2) AU2001247683B2 (enExample)
BR (1) BR0109517A (enExample)
CA (1) CA2404712A1 (enExample)
CZ (1) CZ20023220A3 (enExample)
DE (1) DE60138611D1 (enExample)
ES (1) ES2325055T3 (enExample)
HU (1) HUP0301690A3 (enExample)
IL (1) IL151373A0 (enExample)
MX (1) MXPA02009463A (enExample)
MY (1) MY127082A (enExample)
NO (1) NO20024610L (enExample)
PE (1) PE20011291A1 (enExample)
RU (1) RU2264217C2 (enExample)
TW (1) TWI310684B (enExample)
UY (1) UY26635A1 (enExample)
WO (1) WO2001072721A2 (enExample)
ZA (1) ZA200207766B (enExample)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022461A1 (de) * 1996-11-18 1998-05-28 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel
JP4579351B2 (ja) * 1996-12-03 2010-11-10 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ エポチロンの合成とその中間体及びその類似物並びにその使用
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) * 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
AU2002211427A1 (en) * 2000-10-05 2002-04-15 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
AU2002214649A1 (en) * 2000-10-16 2002-04-29 Neopharm, Inc. Liposomal formulation of mitoxantrone
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
CZ305799B6 (cs) * 2001-03-14 2016-03-23 Bristol-Myers Squibb Company Kombinace analogů epothilonu a chemoterapeutických činidel pro léčení proliferačních nemocí
CA2444867C (en) * 2001-05-16 2010-08-17 Novartis Ag Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
DE60224299T2 (de) * 2001-10-25 2008-12-11 Novartis Ag Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
US7074921B2 (en) * 2001-11-13 2006-07-11 Bristol Myers Squibb Company Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
KR20040066921A (ko) * 2001-12-20 2004-07-27 브리스톨-마이어스스퀴브컴파니 생체이용률이 향상된 경구 활성 탁산 유도체의 제약조성물
US20030147813A1 (en) * 2002-02-07 2003-08-07 John Lyons Method for treating chronic myelogenous leukemia
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
MXPA04010640A (es) * 2002-05-17 2005-08-16 Aventis Pharma Sa Uso de docetaxel/doxorrubicina/ciclofosfamida en la terapia adyuvante de cancer de mama y ovario.
EP2316922B1 (en) * 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
US6627614B1 (en) * 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
RU2379032C9 (ru) * 2002-06-10 2010-03-27 Новартис Аг Комбинации, включающие эпотилоны, и их фармацевтическое применение
PL372070A1 (en) * 2002-06-10 2005-07-11 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2496477C (en) * 2002-08-23 2012-10-16 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20040209930A1 (en) * 2002-10-02 2004-10-21 Carboni Joan M. Synergistic methods and compositions for treating cancer
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
WO2005000230A2 (en) * 2003-06-05 2005-01-06 Charles Achkar Methods of treating hyperproliferative cell disorders
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
NZ601544A (en) * 2003-08-27 2013-11-29 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
WO2005046665A1 (en) * 2003-11-13 2005-05-26 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and a erbb1/2 receptor inhibitor
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
US7612071B2 (en) * 2004-03-12 2009-11-03 Syntrix Biosystems, Inc. Compositions and methods employing aminopterin
EP1732549A4 (en) * 2004-03-18 2009-11-11 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
JP2007538004A (ja) * 2004-03-18 2007-12-27 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089502A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
KR20060130764A (ko) * 2004-03-23 2006-12-19 아스트라제네카 아베 병용 요법
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
ATE478894T1 (de) * 2004-04-15 2010-09-15 Genencor Int Anti-cea scfv-beta-lactamase konstrukte (cab moleküle) in adept
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
JP2008506681A (ja) * 2004-07-16 2008-03-06 ファイザー・プロダクツ・インク 抗ｉｇｆ−１ｒ抗体を用いる非血液性の悪性腫瘍の併用療法
GB0419071D0 (en) 2004-08-26 2004-09-29 Mgx Internat Ltd Display device
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
EP2283831A3 (en) * 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomakers for pre-selection of patients for anti-IGF1R therapy
PT1839662E (pt) * 2005-01-19 2010-04-28 Zeria Pharm Co Ltd Agente antitumoral
ZA200706804B (en) * 2005-02-03 2008-10-29 Gen Hospital Corp Method for treating gefitinib resistant cancer
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
RU2276613C1 (ru) * 2005-03-17 2006-05-20 Российская медицинская академия последипломного образования Министерства здравоохранения Российской Федерации (РМАПО МЗ РФ) Способ лечения злокачественных опухолей головки поджелудочной железы
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
EP1879587A2 (en) * 2005-04-15 2008-01-23 Schering Corporation Methods and compositions for treating or preventing cancer
DK1877102T3 (da) * 2005-04-28 2014-07-21 Danisco Us Inc Tab-molekyler
AR053272A1 (es) 2005-05-11 2007-04-25 Hoffmann La Roche Determinacion de responsivos a la quimioterapia
CN101287761A (zh) * 2005-06-15 2008-10-15 先灵公司 抗-igf1r抗体制剂
FR2887454B1 (fr) * 2005-06-28 2009-06-05 Sanofi Aventis Sa Combinaisons antitumorales contenant des derives du taxane et des sigma ligands
CA2626326C (en) 2005-11-04 2021-02-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
MX2008010635A (es) 2006-02-16 2008-10-28 Schering Corp Derivados de pirrolidina como inhibidores de cinasa regulada por señales extracelulares.
WO2007103828A2 (en) * 2006-03-02 2007-09-13 The Board Of Regents Of The University Of Texas System Fluorocytidine derivatives and cox-2 inhibitors for the treatment of cancer
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
RU2325914C2 (ru) * 2006-06-15 2008-06-10 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ лечения операбельного рака молочной железы
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
US20080085881A1 (en) * 2006-10-06 2008-04-10 Aimery De Gramont Stop-and-go oxaliplatin treatment regimens
WO2008065409A2 (en) * 2006-12-01 2008-06-05 Betagenon Ab Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
EP2131849B1 (en) * 2007-03-02 2011-10-26 The University Of Wollongong Compositions and methods for delivery of anti-cancer agents
WO2008115478A2 (en) * 2007-03-19 2008-09-25 University Of Medicine And Dentistry Of New Jersey Method of cancer detection and treatment
WO2009035718A1 (en) * 2007-09-10 2009-03-19 Curis, Inc. Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
WO2009033204A1 (en) * 2007-09-12 2009-03-19 University Of Wollongong Multi-component compositions and methods for delivery of anti-cancer agents
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2402138T3 (es) 2007-12-28 2013-04-29 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Terapia contra el cáncer con un parvovirus combinado con quimioterapia
USRE45471E1 (en) * 2008-01-28 2015-04-14 Nanocarrier Co., Ltd. Pharmaceutical composition or combination drug
WO2009105500A1 (en) 2008-02-21 2009-08-27 Schering Corporation Compounds that are erk inhibitors
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
CA2725390C (en) * 2008-04-08 2014-09-23 Syndax Pharmaceuticals, Inc. Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
RU2365370C1 (ru) * 2008-04-29 2009-08-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН Способ лечения рака легкого
DK2310011T3 (da) * 2008-06-17 2013-10-14 Wyeth Llc Antineoplastiske kombinationer indeholdende hki-272 og vinorelbin
WO2010057006A1 (en) * 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
EP2370103B1 (en) * 2008-11-28 2016-03-23 Novartis AG Pharmaceutical combinations comprising an isoxazole derived hsp90-inhibitor and the her2 inhibitor trastuzumab
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099364A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease
EP2500036B1 (en) * 2011-03-18 2014-05-07 Metheresis Translational Research SA MET inhibitors for enhancing radiotherapy efficacy
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN103374000B (zh) * 2012-04-13 2015-11-11 中国科学院广州生物医药与健康研究院 嘧啶并二氮杂卓类化合物及其药用组合物和应用
SG10201912985RA (en) 2013-07-12 2020-02-27 Ophthotech Corp Methods for treating or preventing ophthalmological conditions
CN107043456B (zh) * 2017-04-19 2019-05-17 川北医学院 对氧环己酮与l-苯丙氨酸氮芥共聚物及其应用
CA3068256A1 (en) 2017-06-21 2018-12-27 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
CA3103130A1 (en) 2018-06-13 2019-12-19 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric antigen receptor targeting cancer cells
US11068254B1 (en) 2020-06-10 2021-07-20 Cigna Intellectual Property, Inc. Systems and methods for generating and managing domain-based technology architecture
WO2022256656A1 (en) * 2021-06-03 2022-12-08 University Of Cincinnati Bzd-1 as a chemosensitizer of cancer
CN120695174A (zh) * 2021-07-01 2025-09-26 江苏先声生物制药有限公司 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
US11879010B2 (en) 2021-09-30 2024-01-23 The Charlotte Mecklenburg Hospital Authority Methods and compositions for pretargeted immunotherapy
CN114712377B (zh) * 2022-04-26 2023-08-15 江苏师范大学 断血流皂苷a在制造药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
DE19706584C2 (de) * 1997-02-21 2002-09-26 Aeg Energietechnik Gmbh Hochtemperaturbrennstoffzellen mit Erwärmung des Reaktionsgases
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
WO1999002573A1 (en) * 1997-07-08 1999-01-21 Union Carbide Chemicals & Plastics Technology Cor Poration Method for reducing sheeting during olefin polymerization
CZ298511B6 (cs) 1997-12-22 2007-10-24 Schering Corporation Použití benzocykloheptapyridinových sloucenin proprípravu farmaceutického prípravku pro použití v kombinaci s antineoplastickým lécivem a/nebo radioterapií k lécení proliferacních onemocnení
TR200102109T2 (tr) * 1999-01-21 2001-12-21 Bristol-Myers Squibb Company Ras-farnesiltransferazı inhibitörü ve sülfobütileter-7-ß-siklodekstrin veya 2-hidroksipropil-ß-siklodekstrin kompleksi ve metod.

Also Published As

Publication number Publication date
BR0109517A (pt) 2006-08-29
US6537988B2 (en) 2003-03-25
UY26635A1 (es) 2001-10-25
KR20020084254A (ko) 2002-11-04
RU2264217C2 (ru) 2005-11-20
WO2001072721A3 (en) 2002-06-13
NO20024610D0 (no) 2002-09-26
EP1272193B1 (en) 2009-05-06
RU2002129000A (ru) 2004-03-27
EP1272193A2 (en) 2003-01-08
DE60138611D1 (de) 2009-06-18
AU4768301A (en) 2001-10-08
JP2003528864A (ja) 2003-09-30
AR028296A1 (es) 2003-04-30
CA2404712A1 (en) 2001-10-04
IL151373A0 (en) 2003-04-10
CN1419452A (zh) 2003-05-21
ATE430570T1 (de) 2009-05-15
CZ20023220A3 (cs) 2003-11-12
ZA200207766B (en) 2003-01-20
CN100384424C (zh) 2008-04-30
HUP0301690A2 (hu) 2003-08-28
NO20024610L (no) 2002-11-25
ES2325055T3 (es) 2009-08-25
JP5110756B2 (ja) 2012-12-26
MXPA02009463A (es) 2003-04-10
US20020002162A1 (en) 2002-01-03
MY127082A (en) 2006-11-30
WO2001072721A2 (en) 2001-10-04
PE20011291A1 (es) 2002-01-13
TWI310684B (en) 2009-06-11
AU2001247683B2 (en) 2006-01-12

Similar Documents

Publication Publication Date Title
AU4768301A (en) Synergistic methods and compositions for treating cancer
AU6147401A (en) Compositions and methods for the treatment of cancer
AP2006003708A0 (en) Methods and compositions for treating flavivirusesand pestiviruses
HUP0201436A3 (en) Methods and compositions for treating solid tumors
IL144517A0 (en) Compositions and methods for treating cataracts
AU2003284242A8 (en) Methods and compositions for use in treating cancer
IL160388A0 (en) Topical compositions and methods for treating pain
EP1229934A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER BY MEANS OF IMMUNO-CONJUGATES AND CHEMOTHERAPEUTIC AGENTS
AU2003293194A8 (en) Compositions and methods for treating prostate cancer
ATE279190T1 (de) Synergistische zusammensetzungen zur krebsbehandlung
EP1468118A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
AU2003230750A1 (en) Compositions and methods for treating cancer
EP1572118A4 (en) METHOD AND COMPOSITIONS FOR TREATING CANCER WITH 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216
AU5160201A (en) Compositions comprising natural agents for treatment of cancer
PL352931A1 (en) Compositions and uses of et743 for treating cancer
EP1351647A4 (en) COMPOSITIONS AND METHODS FOR TREATING HYPERPIGMENTATION
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
AU2001278738A1 (en) Medicinal compositions for preventing and treating cancer
AU2003298708A8 (en) Gpc99 and gpc99a: methods and compositions for treating cancer
IL154354A0 (en) Composition for prophylaxis and treatment of cancer
AU2001238179A1 (en) Method and compositions for treating hepatocellular cancer
AU2003275433A8 (en) Compositions and methods for treating pain
AU2002360454A8 (en) Methods and compositions for treating cancer
HK1050630A (en) Synergistic methods and compositions for treating cancer
AU2002342188A8 (en) Methods and compositions for treating flavivirus-mediated disease

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees